GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: hazard ratio stopped being a problem at week 51 — 52 comments in the full submission. View in context.
2.4k
c/trialwatch·submitted 9 months ago by u/emil_agyeman

small win: hazard ratio stopped being a problem at week 51

Paperbranch of 5 comments

Quick one. Canada here. SURPASS works very differently where I live than in the threads that dominate the front page, and I keep seeing people confidently given advice that simply does not apply outside the US. Specifics: the route I used took 4 weeks and cost roughly what I expected. The admin was worse than the…

Read the full submission and all 52 comments →

This branch

5 comments, started 9 months ago
u/nils_tulloch244 points·9 months ago
the VendorInvestigate number or it did not happen
replysharereportpermalink
u/renal_outcomes_rnephro-curious94 points·9 months ago

event rates are more informative than hazard ratios alone

replysharereportpermalink
u/emil_agyemanOP52 points·9 months ago

Yeah, absolute numbers matter more than the press release.

replysharereportpermalink
u/enzo_ferrari29 points·9 months ago

event rates are more informative than hazard ratios alone

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →